Vector-borne diseases (VBDs), transmitted by vectors such as mosquitoes, ticks, and fleas, pose a significant health challenge in India. The country's diverse climatic conditions, coupled with high population density, create an environment conducive for the transmission of VBDs.
India is a hotspot for VBDs, with Malaria, Dengue, and Chikungunya being the most prevalent. The World Health Organization reports that India accounts for 4% of global malaria cases. Furthermore, Dengue cases have been on a steady rise, with over 100,000 cases reported annually. Chikungunya, though less prevalent, has caused significant outbreaks in the past.
Managing VBDs in India is fraught with challenges. The vast geographical expanse, varied climatic conditions, and socio-economic disparities render uniform implementation of control measures difficult. Additionally, the lack of public awareness and inadequate diagnostic facilities contribute to the problem.
The Integrated Disease Surveillance Programme (IDSP) and the National Vector Borne Disease Control Programme (NVBDCP) are central to India's strategy for managing VBDs. These initiatives focus on early detection, prompt treatment, and vector control. However, strengthening diagnostic facilities, enhancing public awareness, and fostering inter-sectoral coordination are imperative for effective VBD management.
Healthcare professionals play a crucial role in managing VBDs. Their responsibilities range from patient care and treatment to community education and participation in surveillance activities. They must stay updated on the latest developments in VBD management and adapt their practices accordingly.
While significant strides have been made in controlling VBDs in India, the battle is far from over. A multi-pronged approach involving government agencies, healthcare professionals, and the community at large is essential to curb the menace of these diseases.
1.
Year in Review: Non-Small Cell Lung Cancer
2.
Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat
3.
The need for more Latinx participants in Alzheimer's trials is urgent.
4.
Why palliative care goes hand in hand with treatment for people with cancer: Q&A
5.
MRD-Guided Azacitidine May Delay Relapse in AML, MDS
1.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
2.
The Danger of Methemoglobinemia and How to Prevent It
3.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
4.
Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain
5.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Thromboprophylaxis In Medical Settings
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation